Tumor mutation burden (TMB) is a measure of the number of mutations in the tumor genome, which reflects the neoantigen load and immunogenicity of the tumor, and high TMB is associated with a favorable response to anti-PD-1 therapy in many types of cancer (12). This evidence concerns the gene PDCD1 and cancer.